STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Companies Micro-Cap
scientist-2

Conduit Pharmaceuticals Secures Exclusive Licensing Agreement with AstraZeneca for Novel Therapeutics

byLiliana Vida
August 8, 2024
in Micro-Cap, Pharmaceuticals
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

Phase II Trials Set to Begin on Glucokinase Activators and Myeloperoxidase Inhibitor Targeting Autoimmune Disorders and Male Infertility

Conduit Pharmaceuticals (CDT) has announced a significant step forward in its mission to develop innovative treatments for unmet medical needs. The company has entered into an exclusive licensing agreement with pharmaceutical giant AstraZeneca, securing the rights to develop three promising compounds: AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase (MPO) inhibitor. These assets, which have already shown favorable preclinical and Phase I data, will be advanced by Conduit into Phase II clinical trials targeting autoimmune disorders and idiopathic male infertility.

A Strategic Alliance with AstraZeneca

Under the terms of the agreement, AstraZeneca grants Conduit an exclusive license to AZD1656 and AZD5658 for all human indications, as well as to AZD5904 for use in treating idiopathic male infertility. This partnership reflects Conduit’s strategic approach to drug development, which involves acquiring assets that have already undergone substantial preclinical and clinical testing, thereby reducing the time and resources needed to bring new treatments to market.

As part of the deal, AstraZeneca will receive shares of common stock in Conduit and a share of sublicense revenues, including upfront payments, milestones, and royalties from future partnerships. This arrangement underscores the mutual benefit both companies seek from the collaboration. AstraZeneca will also transfer valuable know-how related to the compounds and provide Conduit with certain quantities of AZD1656, AZD5658, and AZD5904 from its inventory, further supporting Conduit’s development efforts.

Fast-Tracking Development of Promising Therapeutics

Conduit’s initial focus will be on advancing AZD1656 and AZD5658 through Phase II clinical trials in 2024. These compounds target autoimmune disorders, a category of diseases that impact an estimated 10% of the global population. Autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis, represent a significant area of unmet medical need, with patients often requiring new and more effective treatment options.

AZD1656 and AZD5658, as HK-4 glucokinase activators, have shown potential in modulating glucose levels and influencing immune responses, making them promising candidates for addressing autoimmune conditions. The existing data from AstraZeneca’s Phase I trials provides a solid foundation for Conduit to build upon as it prepares for Phase II studies.

In parallel, Conduit will explore the potential of AZD5904, a myeloperoxidase inhibitor, in treating idiopathic male infertility. Myeloperoxidase is an enzyme linked to oxidative stress and inflammation, which can contribute to various conditions, including infertility. The development of AZD5904 could offer a novel therapeutic approach for men facing infertility, a condition with limited treatment options currently available.

A Unique Business Model

Conduit Pharmaceuticals has carved out a distinct niche in the biopharmaceutical industry by focusing on assets that are already in the later stages of development. Unlike traditional biotech companies that take compounds from discovery through commercialization, Conduit’s strategy involves accelerating the development of assets through Phase II trials. Upon achieving positive results, the company intends to seek exits through third-party license opportunities, thereby minimizing risk while maximizing potential returns.

This business model allows Conduit to bring new therapies to patients more quickly, addressing urgent medical needs without the prolonged timelines associated with early-stage drug development. By leveraging the extensive work already done by AstraZeneca on these compounds, Conduit is positioned to expedite the process of getting these therapies into clinical use.

Looking Ahead

The exclusive licensing agreement with AstraZeneca marks a pivotal moment for Conduit Pharmaceuticals. With access to AZD1656, AZD5658, and AZD5904, Conduit has secured a portfolio of compounds with the potential to make a significant impact on patients’ lives. The company’s commitment to advancing these assets into Phase II trials demonstrates its confidence in their therapeutic potential and its dedication to addressing the needs of patients with autoimmune disorders and idiopathic male infertility.

Dr. David Tapolczay, Chief Executive Officer of Conduit, expressed optimism about the partnership, stating, “The potential of these assets to become important first-in-class medicines for patients is promising. Given the data from AstraZeneca’s clinical trials, we believe there is a strong rationale to initiate Phase II studies in multiple indications to progress to commercialization of these assets.”

As Conduit prepares to initiate these trials in 2024, the biopharmaceutical community will be closely watching the outcomes, anticipating the next steps in the journey of these novel therapeutics. With a strategic partner like AstraZeneca and a clear pathway to development, Conduit is poised to make significant strides in the treatment of autoimmune disorders and male infertility.

You might like this article:5 Undervalued Stocks You Should Know About

Tags: BreakingGrowthMoversNewsStock Market
Previous Post

5 Undervalued Stocks You Should Know About

Next Post

Eli Lilly Surpasses Expectations: Blockbuster Drugs Drive $3 Billion Revenue Hike in 2024 Outlook

Related Posts

investing

Top Movers Today:

byLuca Blaumann
September 22, 2026
0

$LHSW $DCOY $GRML $JAGX $FLNA $LHSW - Lianhe Sowell International Group shares are trading higher after the company announced it...

Fusion Fuel Expands UAE Footprint With $1.4 Million in New LPG Engineering Projects

byLuca Blaumann
August 20, 2026
0

Al Shola Gas secured 10 projects supporting more than 3,450 residential units while a new hospitality agreement could generate up...

drugs-4

Hims & Hers Reports Strong Earnings Growth as Telehealth Demand Accelerates

byLiliana Vida
May 11, 2026
0

Subscription growth, personalized healthcare offerings, and expanding wellness categories drive momentum for digital health platform Hims & Hers Health (HIMS)...

Next Post
drugs-5

Eli Lilly Surpasses Expectations: Blockbuster Drugs Drive $3 Billion Revenue Hike in 2024 Outlook

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers

D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Based on Your Interest

Artificial Intelligence

CoreWeave Q3 Revenue Surges Nearly 170% to $3.66 Billion as AI Demand Accelerates

November 11, 2026
Artificial Intelligence

CoreWeave Earnings Preview: Why Guidance Matters More Than Q3 Results

November 10, 2026
investing
Artificial Intelligence

D-Wave Quantum Q3 Revenue Rises 21% as Bookings Surge and Quantum Adoption Expands

November 10, 2026

Recommended

Auto Manufacturers

Lucid Secures $1.75 Billion Liquidity Boost From Saudi PIF to Support Turnaround

November 10, 2026
Artificial Intelligence

KULR Technology Revenue Surges 197% in Q3 as Battery Sales Nearly Quadruple

November 10, 2026
Aerospace & Defense

Rocket Lab Q3 Revenue Surges 73% to $268 Million, Beating Wall Street Expectations

November 9, 2026
Artificial Intelligence

IonQ Shares Climb as Company Expands Government Reach Through Carahsoft Partnership

November 9, 2026
Aerospace & Defense

AST SpaceMobile and Rakuten Launch Joint Venture Backed by $1 Billion in Japanese Government Funding

November 9, 2026
Stoxpo

Follow us on social media:

Highlights

  • Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders
  • KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems
  • SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results
  • Qualcomm CEO Rejects AI Market Correction Fears as Company Expands Into Data Centers
  • D-Wave Quantum Q3 Revenue Climbs 21% as Backlog Surges Over 1,200%

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Anthropic Leveraged ETFs: What GraniteShares’ AIL and ANS Offer Traders

November 20, 2026

KULR Technology Secures $14.8 Million Purchase Order for Advanced Energy Storage Systems

November 18, 2026
chemistry-2

SELLAS Life Sciences Stock Soars 170% Following Positive Phase 3 Leukemia Vaccine Results

November 17, 2026
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.